Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 17,786 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Repare Therapeutics Inc | RPTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.03 | -0.82% | 3.61 | 09:20:33 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.64 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 276 | 17,786 | - | 2.98 - 13.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:21:03 | 1 | $ 3.62 | USD |
Repare Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 153.54M | 42.18M | - | 51.13M | -93.8M | -2.22 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Repare Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.48 | 3.96 | 3.26 | 3.75 | 1,132,916 | 0.13 | 3.74% |
| 1 Month | 3.88 | 3.9799 | 2.98 | 3.63 | 374,233 | -0.27 | -6.96% |
| 3 Months | 6.83 | 7.45 | 2.98 | 4.23 | 196,143 | -3.22 | -47.14% |
| 6 Months | 3.67 | 8.49 | 2.98 | 5.44 | 247,959 | -0.06 | -1.63% |
| 1 Year | 10.64 | 13.85 | 2.98 | 6.36 | 208,631 | -7.03 | -66.07% |
| 3 Years | 32.98 | 35.75 | 2.98 | 13.51 | 237,184 | -29.37 | -89.05% |
| 5 Years | 32.05 | 46.44 | 2.98 | 16.02 | 212,971 | -28.44 | -88.74% |
Repare Therapeutics Description
| Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. |
